Vasopressin and oxytocin gene expression in intact rats and under catecholamine deficiency during ontogenesis.
The development of the hypothalamic vasopressin (VP) and oxytocin (OT) systems has been studied in rats from the 16th embryonic day (E16) until the 11th postnatal day (P11). The VP and OT mRNA-producing neurons were identified on cryostat sections by in situ hybridization using oligonucleotide probes labeled by [35S], [3H] or digoxigenin. Moreover, VP and OT gene expressions were evaluated either at E21 or at P11 following chronic depletion of catecholamines (CA). For this purpose, pregnant rats were daily injected with alpha-methyl-m(p)-tyrosine from gestational day 13 to 20 while neonates were daily injected with alpha-methyl-m(p)-tyrosine and neurotoxin 6-hydroxydopamine from postnatal day 2 to 10. No VP mRNA- or OT mRNA-expressing cells were observed in the hypothalamus of intact fetuses at E16, while 2 days later rather numerous VP and OT neurons occupied the anterior hypothalamus. One major bilateral group of VP and OT neurons was located in the supraoptic nucleus (SON). Less numerous labeled cells were found in the developing paraventricular nucleus (PVN). Some VP and OT neurons were also spread along the ventrolateral surface of the hypothalamus from the level of the median eminence, caudally, to the level of the optic nerves, rostrally. From E18 until birth, the OT neurons were localized in the dorsal portion of the SON, while its ventral portion was occupied by the VP neurons. The VP mRNA- and OT mRNA-expressing cells seemed to increase both in size and in number over the perinatal period. Frequent relatively long neuronal processes contained VP and OT mRNAs in fetuses and in newborns. When performed during the second half of the fetal life, the chronic depletion of CA did not cause any change in the VP and OT mRNA concentrations in the SON and PVN of fetuses. By contrast, similar treatment of neonates resulted in a significant increase of both mRNA levels in the SON. These data suggest that at least in the SON VP and OT gene expression might be under the inhibitory control of CA during the neonatal period.
Trembleau
A
A
Départment de Neurobiologie des Signaux Intercellulaires, CNRS URA 1488 Université P. et M. Curie, Paris, France.
Ugrumov
M
M
Roche
D
D
Calas
A
A
D000818:Animals; D000831:Animals, Newborn / Q000502:physiology; D002395:Catecholamines / Q000502:physiology*; D005260:Female; D018507:Gene Expression Regulation, Developmental / Q000502:physiology*; D017403:In Situ Hybridization; D008781:Methyltyrosines / Q000494:pharmacology; D009474:Neurons / Q000502:physiology; D010121:Oxytocin / Q000096:biosynthesis* / Q000235:genetics; D010286:Paraventricular Hypothalamic Nucleus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D011247:Pregnancy; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D013493:Suprachiasmatic Nucleus / Q000166:cytology / Q000196:embryology / Q000378:metabolism*; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors; D014667:Vasopressins / Q000096:biosynthesis* / Q000235:genetics; D019805:alpha-Methyltyrosine
D002395:Catecholamines; D008781:Methyltyrosines; D012333:RNA, Messenger; D014667:Vasopressins; D010121:Oxytocin; D019805:alpha-Methyltyrosine; D014446:Tyrosine 3-Monooxygenase